<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ye F</submitter><funding>Natural Science Foundation of Guangdong</funding><funding>Science and Technology Planning Projects of Guangdong</funding><funding>National Natural Science Foundation of China</funding><pagination>11-20</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375573</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>51</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Invasive micropapillary carcinoma (IMPC) is a rare histological subtype of breast cancer. The outcome of IMPC remains controversial; we conducted a meta-analysis of propensity score matching (PSM) studies to evaluate the prognostic difference between IMPC and invasive ductal carcinoma (IDC).&lt;h4>Methods&lt;/h4>We searched PubMed, EMBASE and the Cochrane library for PSM studies comparing survival data between IMPC and IDC. The summarized odds ratios (ORs) and 95% confidence interval (95% CI) are calculated by STATA software utilizing fixed-effect or random-effect models, depending on the heterogeneity of the eligible studies.&lt;h4>Results&lt;/h4>Eight PSM studies including 2102 IMPC patients are included in the meta-analysis. Compared with IDC, IMPC has a similar overall survival (OS) (estimated OR = 0.87, 95% CI: 0.61-1.25), but a shorter relapse free survival (RFS) (estimated OR = 1.31, 95% CI: 1.06-1.61); the shorter RFS might owe to the significantly higher loco-regional recurrence rate of IMPC (estimated OR = 3.60, 95% CI: 1.99-6.52). Funnel plots and Egger's tests are used to evaluate publication bias and the p value for OS and RFS are 0.036 and 0.564 respectively.&lt;h4>Conclusions&lt;/h4>Our results demonstrate that compared with IDC, IMPC exhibits a similar, even favorite OS, but a shorter RFS; and the shorter RFS might owe to the significantly higher loco-regional recurrence rate of IMPC. These results could contribute to the individualized therapy and follow-up strategies for IMPC patients.</pubmed_abstract><journal>Breast (Edinburgh, Scotland)</journal><pubmed_title>Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies.</pubmed_title><pmcid>PMC7375573</pmcid><funding_grant_id>2018A0303130285</funding_grant_id><funding_grant_id>81872152</funding_grant_id><funding_grant_id>2017A020215197</funding_grant_id><pubmed_authors>Xie X</pubmed_authors><pubmed_authors>Yu P</pubmed_authors><pubmed_authors>Liu P</pubmed_authors><pubmed_authors>Ye F</pubmed_authors><pubmed_authors>Yang A</pubmed_authors><pubmed_authors>Li N</pubmed_authors><pubmed_authors>Tang H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies.</name><description>&lt;h4>Background&lt;/h4>Invasive micropapillary carcinoma (IMPC) is a rare histological subtype of breast cancer. The outcome of IMPC remains controversial; we conducted a meta-analysis of propensity score matching (PSM) studies to evaluate the prognostic difference between IMPC and invasive ductal carcinoma (IDC).&lt;h4>Methods&lt;/h4>We searched PubMed, EMBASE and the Cochrane library for PSM studies comparing survival data between IMPC and IDC. The summarized odds ratios (ORs) and 95% confidence interval (95% CI) are calculated by STATA software utilizing fixed-effect or random-effect models, depending on the heterogeneity of the eligible studies.&lt;h4>Results&lt;/h4>Eight PSM studies including 2102 IMPC patients are included in the meta-analysis. Compared with IDC, IMPC has a similar overall survival (OS) (estimated OR = 0.87, 95% CI: 0.61-1.25), but a shorter relapse free survival (RFS) (estimated OR = 1.31, 95% CI: 1.06-1.61); the shorter RFS might owe to the significantly higher loco-regional recurrence rate of IMPC (estimated OR = 3.60, 95% CI: 1.99-6.52). Funnel plots and Egger's tests are used to evaluate publication bias and the p value for OS and RFS are 0.036 and 0.564 respectively.&lt;h4>Conclusions&lt;/h4>Our results demonstrate that compared with IDC, IMPC exhibits a similar, even favorite OS, but a shorter RFS; and the shorter RFS might owe to the significantly higher loco-regional recurrence rate of IMPC. These results could contribute to the individualized therapy and follow-up strategies for IMPC patients.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jun</publication><modification>2025-04-19T11:41:24.991Z</modification><creation>2025-04-19T11:41:24.991Z</creation></dates><accession>S-EPMC7375573</accession><cross_references><pubmed>32172190</pubmed><doi>10.1016/j.breast.2020.01.041</doi></cross_references></HashMap>